Home/Pipeline/Psi-GAD

Psi-GAD

Generalized Anxiety Disorder (GAD)

Phase 2Active - Trial ongoingACTRN12623000526673

Key Facts

Indication

Generalized Anxiety Disorder (GAD)

Phase

Phase 2

Status

Active - Trial ongoing

Company

Incannex Healthcare

About Incannex Healthcare

Incannex Healthcare is a clinical-stage biotech focused on developing proprietary cannabinoid and psychedelic-based therapies for conditions with high unmet need, including sleep apnea and anxiety disorders. The company has progressed its lead asset, IHL-42X for OSA, into pivotal Phase 2/3 trials and is advancing a psilocybin program for GAD. Its strategy centers on securing intellectual property around novel formulations and treatment protocols to build a valuable clinical pipeline, funded through its dual listing on the ASX and NASDAQ.

View full company profile

Therapeutic Areas

Sleep Disorders Psychiatry Inflammatory Diseases

Other Generalized Anxiety Disorder (GAD) Drugs

Drug	Company	Phase	Status
Generalized Anxiety Disorder Treatment	Viatris (2)	Approved (Japan)	Active
NTX-1955	Newleos	Phase 1b	Active
Luvesilocin (RE104)	Reunion Neuroscience	Pre-clinical/Planned	Active
DT120	Definium Therapeutics	Phase 3	Actively Recruiting
HLP004	Helus Pharma	Phase 2	Signal Detection Study Completed
CYB004	Helus Pharma	Phase 2	Enrollment Completed
BNC210	Neuphoria Therapeutics	Phase 2	Completed